SEC Form SC 13G filed by Savara Inc.

SEC Form SC 13G filed by Savara Inc.

Recent Analyst Ratings for $SVRA

$SVRA Press Releases

$SVRA Insider Purchases

$SVRA Insider Trading

$SVRA Leadership Updates

$SVRA Analyst Ratings

$SVRA Financials

$SVRA SEC Filings

$SVRA Large Ownership Changes

Recent Analyst Ratings for
$SVRA

$SVRA
Press Releases

$SVRA
Insider Purchases

$SVRA
Insider Trading

$SVRA
Leadership Updates

$SVRA
Analyst Ratings

$SVRA
Financials

$SVRA
SEC Filings

$SVRA
Large Ownership Changes

Chat with this insight

Fastest customizable press release news feed in the world

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

Savara Announces New Employment Inducement Grant

Savara Announces Participation in Jefferies Global Healthcare Conference

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

Director Mccracken Joseph S bought $59,072 worth of shares (20,000 units at $2.95), increasing direct ownership by 10% to 210,837 units (SEC Form 4)

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

New insider Mccabe Kathleen R. claimed ownership of 558,582 shares (SEC Form 3)

Live Leadership Updates

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

Savara Announces Resignation of Chief Medical Officer

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Savara downgraded by H.C. Wainwright with a new price target

Wells Fargo initiated coverage on Savara with a new price target

Savara downgraded by Evercore ISI with a new price target

Live finance-specific insights

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

SEC Form 8-K filed by Savara Inc.

SEC Form 8-K filed by Savara Inc.

SEC Form 10-Q filed by Savara Inc.

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Savara Inc.

Amendment: SEC Form SC 13G/A filed by Savara Inc.

Amendment: SEC Form SC 13G/A filed by Savara Inc.

11/27/24 11:01:58 AM ET

$SVRA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SVRA alert in real time by email

SC 13G 1 d891757dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. __)*

Savara Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

805111101

(CUSIP Number)

November 20, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 805111101

(1)

Consists of 4,743,042 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

Consists of 2,298,544 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

Consists of 249,535 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

Consists of 1,369,258 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

Consists of (i) 4,743,042 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 2,298,544 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 249,535 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iv) 1,369,258 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

Consists of (i) 4,743,042 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 2,298,544 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

CUSIP No. 805111101

(1)

(2)	Based on 171,618,944 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 12, 2024.

Item 1(a).

Name of Issuer: Savara Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices: 1717 Langhorne Newtown Road, Suite 300, Langhorne, PA 19047

Item 2(a).

Name of Person Filing:

The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

FHMLSP, L.P.

FHMLSP, L.L.C.

Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”)

FHMLSP Overage, L.P.

FHMLSP Overage, L.L.C.

Frazier Life Sciences XI, L.P. (“FLS XI”)

FHMLS XI, L.P.

FHMLS XI, L.L.C.

Frazier Life Sciences X, L.P. (“FLS X”)

FHMLS X, L.P.

FHMLS X, L.L.C.

James N. Topper (“Topper”)

Patrick J. Heron (“Heron”)

Albert Cha (“Cha”)

James Brush (“Brush”)

Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address and principal business office of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.

1001 Page Mill Rd, Building 4, Suite B

Palo Alto, CA 94304

Item 2(c).

Citizenship:


Entities:	FLSPF	-	Delaware, U.S.A.
	FHMLSP, L.P.	-	Delaware, U.S.A.
	FHMLSP, L.L.C.	-	Delaware, U.S.A.
	FLSPOF	-	Delaware, U.S.A.
	FHMLSP Overage, L.P.	-	Delaware, U.S.A.
	FHMLSP, L.L.C.	-	Delaware, U.S.A.
	FLS XI	-	Delaware, U.S.A.
	FHMLS XI, L.P.	-	Delaware, U.S.A.
	FHMLS XI, L.L.C.	-	Delaware, U.S.A.
	FLS X	-	Delaware, U.S.A.
	FHMLS X, L.P.	-	Delaware, U.S.A.
	FHMLS X, L.L.C.	-	Delaware, U.S.A.

Individuals:	Topper	-	United States Citizen
	Heron	-	United States Citizen
	Cha	-	United States Citizen
	Brush	-	United States Citizen
	Estes	-	United States Citizen

Item 2(d).

Title of Class of Securities: Common Stock

Item 2(e).

CUSIP Number: 805111101

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d–1(b)(1)(ii)(K).

	If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: November 27, 2024	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By: FHMLSP, L.P., its General Partner
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FHMLSP, L.P.
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.
	By: FHMLSP Overage, L.P., its General Partner
	By: FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FHMLSP OVERAGE, L.P.
	By FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FHMLSP OVERAGE, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FRAZIER LIFE SCIENCES XI, L.P.
	By: FHMLS XI, L.P., its General Partner
	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FHMLS XI, L.P.
	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: November 27, 2024	FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FRAZIER LIFE SCIENCES X, L.P.
	By:	FHMLS X, L.P., its General Partner
	By:	FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FHMLS X, L.P.
	By:	FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 27, 2024	By:	*
		James N. Topper

Date: November 27, 2024	By:	*
		Patrick J. Heron

Date: November 27, 2024	By:	**
		Albert Cha

Date: November 27, 2024	By:	**
		James Brush

Date: November 27, 2024	By:	***
		Daniel Estes

Date: November 27, 2024	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Exhibit Index


Exhibit A -		Agreement regarding filing of joint Schedule 13G.

Get the next $SVRA alert in real time by email

Date	Price Target	Rating	Analyst
5/29/2025	$2.00	Buy → Neutral	H.C. Wainwright
12/20/2024	$8.00	Overweight	Wells Fargo
11/13/2024	$7.00 → $5.00	Outperform → In-line	Evercore ISI
2/15/2024	$8.00	Mkt Outperform	JMP Securities
11/7/2023	$7.00	Buy	Guggenheim
5/16/2023	$2.00 → $4.00	Hold → Buy	Jefferies
3/31/2023	$2.00	Buy → Hold	Jefferies

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware